

CIN No:- U24230PB2006PLC030341
GST No:- 02AAHCA5390H2ZT



Ref. No. ANG/2017-18/BSE

Date. 21/11/2017.....

To

Department of Corporate Services,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai- 400001

Ref: BSE Security Code 540694

Sub: Outcome of Board Meeting pursuant to Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015

Dear Sir/ Madam,

Pursuant to Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, we would like to inform you that Board of Directors in its meeting held on November 21, 2017 (commenced at 5:00 P.M and concluded at 9:30 P.M) has considered and approved the Un-Audited Financial Results of the Company for the Half Year ended September 30, 2017 along with Statement of Assets and Liabilities as at September 30, 2017 and the Limited Review Report of the auditors thereon.

Kindly take this information on your record.

Thanking You,

Yours Faithfully

For ANG Lifesciences India Limited


Rajesh Gupta
(DIN: 01423407)
Managing Director

Factory:
Vill. Kishanpura
P.O. Manpura,
Baddi-Nalagarh Road,
Tehsil-Baddi
Distt. Solan (H.P.)

Regd. Office : SCO-113,
DARBARA COMPLEX,
First Floor, B-BLOCK,
Ranjit Avenue, Amritsar.
Ph. 0183-5070118,5133455,5133475
E mail :- operations@anglifesciences.com
website : www.anglifesciences.com

ANG Life Sciences India Ltd.

CIN : U24230PB2006PLC030341

REGISTERED OFFICE : SCO 113, First Floor, Darbara Complex,

Ranjit Avenue, Amritsar

Email Id : cs@anglifesciences.com, Website : www.anglifesciences.com

UNAUDITED STANDLONE FINANCIALS RESULTS FOR THE HALF YEAR ENDED ON SEPTEMBER 30, 2017

| Serial Number | Particulars | Figures for the half year ended on | | | (In Lacs) |
|---------------|---|------------------------------------|----------------|----------------|----------------|
| | | 30/09/2017 | 31/03/2017 | 30/09/2016 | 31/03/2017 |
| | | (Unaudited) | (Audited) | (UnAudited) | (Audited) |
| I. | INCOME FROM OPERATIONS | | | | |
| | a) Revenue from operations | 2919.49 | 3789.21 | 2977.59 | 6766.81 |
| | b) Other Income | 5.90 | 24.20 | 0.82 | 25.02 |
| | Total Income | 2925.39 | 3813.41 | 2978.41 | 6791.82 |
| II | Expenses: | | | | |
| | Cost of materials consumed | 2234.60 | 2505.19 | 2160.83 | 4666.02 |
| | Purchase of Stock in trade | | | | |
| | Change in inventories of finished , WIP and stock in trade | -282.44 | 205.56 | -94.47 | 111.08 |
| | Employee benefits expense | 273.71 | 184.31 | 228.09 | 412.40 |
| | Finance costs | 75.75 | 83.50 | 69.32 | 152.82 |
| | Depreciation and amortization expense | 55.41 | 64.34 | 52.70 | 117.04 |
| | Other expenses | 435.76 | 582.00 | 369.33 | 951.33 |
| | Total expenses | 2792.79 | 3624.89 | 2785.79 | 6410.68 |
| III | Profit/ (loss) for the period (1-2) | 132.60 | 188.52 | 192.62 | 381.14 |
| IV | Tax expense: | | | | |
| | (1) Current tax | 27.85 | 44.92 | 42.37 | 87.29 |
| | (2) Deferred tax | 0.00 | 11.50 | 0.00 | 11.50 |
| V | Net Profit/ (loss) for the period (3-4) | 104.75 | 132.10 | 150.25 | 282.35 |
| VI | Other Comprehensive Income | | | | |
| VII | Paid-Up Equity Share Capital (Equity Share of Rs 10/- each) | 518.33 | 368.25 | 368.25 | 368.25 |
| VIII | Earnings per equity share: | | | | |
| | (1) Basic | 2.25 | 3.59 | 4.08 | 7.67 |
| | (2) Diluted | 2.25 | 3.59 | 4.08 | 7.67 |

Notes:

- 1) The Audit Committee has received these results and the Board of Directors have approved the above results at their meeting held on November 21/11/2017
- 2) The figures for the half year ended on September 30, 2017 has been received by the statutory Auditors' of the company
- 3) As the company business activities falls with in a single segment, the disclosure requirements of the accounting Standard AS (17) 'segment Reporting' as notified under section 133 of the Companies Act 2013, read with Rule7 of the companies (Accounts) Rules 2014 are not applicable.
- 4) The figures for the corresponding previous period have been regrouped/ reclassified wherever considered necessary to confirm the figures in the current period.
- 5) As per MCA Notification dated 16th February, 2015, companies whose share are listed on SME exchange as referred in ChapterXB of SEBI(issue of capital disclosure requirements) regulations 2009 are exempted from the compulsory requirements of adoption of adoption of IND-AS. As the company is covered under the exempted category, it has not adopted IND -AS for preparation of Financials Results
- 6) There were no Investors complaints pending as on 30/09/2017

Date : 21.11.2017

Place : Amritsar

For ANG Life Sciences India Limited |

(Director)
Rajesh Gupta

(In Rupees)

STATEMENT OF ASSETS AND LIABILITIES AS AT 30TH SEPTEMBER 2017

| Particulars | Figures as at the end of current reporting period | Figures as at the end of previous reporting period |
|---|---|--|
| 1 | 4 | 5 |
| I. EQUITY AND LIABILITIES | | |
| 1 Shareholders' funds | | |
| (a) <u>Share capital</u> | 518.33 | 368.25 |
| (b) <u>Reserves and surplus</u> | 1532.84 | 380.66 |
| 2 Non-current liabilities | | |
| (a) <u>Long term borrowings</u> | 667.30 | 496.30 |
| (b) <u>Deferred Tax Liabilities (Net)</u> | 17.54 | 17.54 |
| (c) <u>Other Long Term Liabilities</u> | | |
| (d) <u>Long Term Provisions</u> | | |
| 3 Current liabilities | | |
| (a) <u>Short Term Borrowings</u> | 700.27 | 661.35 |
| (b) <u>Trade Payables</u> | 1268.86 | 2139.18 |
| (c) <u>Other current liabilities</u> | 243.43 | 529.24 |
| (d) <u>Short-term provisions</u> | 117.41 | 91.29 |
| TOTAL | 5065.98 | 4683.82 |
| II. ASSETS | | |
| Non-current assets | | |
| 1 | | |
| (a) <u>Fixed assets</u> | 887.73 | 897.30 |
| (b) <u>Other non-current assets</u> | 8.79 | 8.79 |
| (c) <u>Deferred Tax Assets (Net)</u> | 0.00 | 0.00 |
| (d) <u>Long term loans and advances</u> | 0.00 | 0.00 |
| (e) <u>Other non-current Investments</u> | 2.00 | 2.00 |
| 2 Current assets | | |
| (a) <u>Current Investments</u> | 0.00 | 0.00 |
| (b) <u>Inventories</u> | 778.85 | 584.08 |
| (c) <u>Trade receivables</u> | 2426.50 | 2555.61 |
| (d) <u>Cash and cash equivalents</u> | 123.35 | 90.97 |
| (e) <u>Short-term loans and advances</u> | 838.26 | 545.06 |
| TOTAL | 5065.98 | 4683.82 |

Date : 21.11.2017
 Place : Amritsar

For ANG Life Sciences India Limited

(Director)
 Rajesh Gupta

Ajay K Khanna & Co
CHARTERED ACCOUNTANTS

Office: 2, Near Medcard Hospitals
Taran taran Road, Amritsar-143022
Email Id : cabhupinder29@gmail.com
Contact number: 98883-07845

**INDEPENDENT AUDITORS LIMITED REVIEW REPORT ON THE UNAUDITED
FINANCIALS RESULTS FOR THE HALF YEAR ENDED 30TH SEPTEMBER 2017**

To,


The Board of Directors,
ANG Lifesciences India Limited
SCO 113, Darbara Complex,
First Floor, B-Block,
Ranjit Avenue, Amritsar-143001

We have reviewed the accompanying statement of unaudited financial results of **ANG Lifesciences India Limited** for the period ended on 30th September, 2017. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, Engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Ajay K Khanna & Co.
Chartered Accountants


(Bhupinder Singh)
Partner
M. No: 513899
FRN : 012303N



DATE:21/11/2017